Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents.

Witzig TE, Timm M, Stenson M, Svingen PA, Kaufmann SH.

Clin Cancer Res. 2000 Feb;6(2):681-92.

2.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
3.

Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.

Verheul HM, Qian DZ, Carducci MA, Pili R.

Cancer Chemother Pharmacol. 2007 Aug;60(3):329-39. Epub 2007 Jan 26.

PMID:
17256134
4.

The differentiation inducers phenylacetate and phenylbutyrate modulate camptothecin sensitivity in colon carcinoma cells in vitro by intracellular acidification.

Cosentini E, Haberl I, Pertschy P, Teleky B, Mallinger R, Baumgartner G, Wenzl E, Hamilton G.

Int J Oncol. 2001 Nov;19(5):1069-74.

PMID:
11605011
7.

Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate.

Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, Nelson WG, Simons JW.

Clin Cancer Res. 1996 Feb;2(2):379-87.

8.

Growth inhibitory effects and radiosensitization induced by fatty aromatic acids on human cervical cancer cells.

Ferrandina G, Filippini P, Ferlini C, Maggiano N, Stoler AB, Fruscella E, Mozzetti S, Mancuso S, Freedman RS, Scambia G, Ranelletti FO.

Oncol Res. 2000;12(9-10):429-40.

PMID:
11697821
9.

In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.

Kano Y, Akutsu M, Tsunoda S, Suzuki K, Ichikawa A, Furukawa Y, Bai L, Kon K.

Leukemia. 2000 Mar;14(3):379-88.

PMID:
10720130
10.

Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate.

Shack S, Miller A, Liu L, Prasanna P, Thibault A, Samid D.

Clin Cancer Res. 1996 May;2(5):865-72.

11.

Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.

Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA.

Cancer Res. 2001 Feb 15;61(4):1477-85.

12.

Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells.

Li XN, Parikh S, Shu Q, Jung HL, Chow CW, Perlaky L, Leung HC, Su J, Blaney S, Lau CC.

Clin Cancer Res. 2004 Feb 1;10(3):1150-9.

13.

Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis.

DiGiuseppe JA, Weng LJ, Yu KH, Fu S, Kastan MB, Samid D, Gore SD.

Leukemia. 1999 Aug;13(8):1243-53.

PMID:
10450753
14.

Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells.

Li ZM, Jiang WQ, Zhu ZY, Zhu XF, Zhou JM, Liu ZC, Yang DJ, Guang ZZ.

Cancer Biol Ther. 2008 Jan;7(1):51-60. Epub 2007 Oct 8.

PMID:
17938578
15.

Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate.

Miller AC, Whittaker T, Thibault A, Samid D.

Int J Radiat Biol. 1997 Aug;72(2):211-8.

PMID:
9269314
16.

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.

Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.

Haematologica. 2002 Jan;87(1):33-43.

17.

In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine.

Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou PS, Weidmann E.

Haematologica. 2001 May;86(5):485-93.

18.

Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.

Adjei AA, Budihardjo II, Rowinsky EK, Kottke TJ, Svingen PA, Buckwalter CA, Grochow LB, Donehower RC, Kaufmann SH.

Clin Cancer Res. 1997 May;3(5):761-70.

19.

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

Di Gaetano N, Xiao Y, Erba E, Bassan R, Rambaldi A, Golay J, Introna M.

Br J Haematol. 2001 Sep;114(4):800-9.

PMID:
11564066
20.

The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.

Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, Takeshita K, Takeshita A, Ohno R.

Leukemia. 1998 Sep;12(9):1383-91.

PMID:
9737686

Supplemental Content

Support Center